◆英語タイトル:Living Cell Technologies Ltd (LCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10037
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ニュージーランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Living Cell Technologies Ltd (LCT) is a biotechnology company that develops cell-based therapeutics for the treatment of neurological diseases, diabetes, and stroke and hearing loss. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. LCT develops its candidates based on its proprietary encapsulation technology, Immupel. Its lead product candidate, NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. It is in Phase IIb clinical trials for the treatment of Parkinson’s disease. The company is also developing the candidate in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS). LCT’s joint venture, Diatranz Otsuka Limited develops Diabecell, a cell therapy for type 1 diabetes. LCT is headquartered in Auckland, the New Zealand.
Living Cell Technologies Ltd (LCT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Living Cell Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Living Cell Technologies Enters into Research Agreement with The Centre for Brain Research 11
Licensing Agreements 12
Living Cell Technologies to Enter into Licensing Agreement with Diatranz Otsuka 12
Living Cell Technologies Enters into Licensing Agreement with Otsuka Pharma 13
Equity Offering 14
Living Cell Technologies to Raise Funds through Share Purchase Plan 14
Living Cell Technologies Raises USD2.8 Million in Private Placement of Shares 15
Acquisition 16
Otsuka Pharma to Acquire 50% Stake in Diatranz Otsuka from Living Cell Technologies for USD3 Million 16
Living Cell Technologies Ltd – Key Competitors 17
Living Cell Technologies Ltd – Key Employees 18
Living Cell Technologies Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Joint Venture 20
Recent Developments 21
Financial Announcements 21
Jul 26, 2018: Living Cell Technologies: Appendix 4C Quarterly Cash Flow Report 30 June 2018 21
Aug 23, 2017: Living Cell Technologies: Preliminary Final Report 30 June 2017 22
Jul 20, 2017: Living Cell Technologies: Appendix 4C Quarterly Cash Flow Report 30 June 2017 23
Corporate Communications 24
Aug 31, 2018: Living Cell Technologies: Roy Austin has stepped down from his role as Chairman and from his post 24
Other Significant Developments 25
Oct 29, 2018: Living Cell Technologies: Appendix 4c quarterly cash flow report 30 September 2018 25
Apr 11, 2018: LCT Strategy Update 26
Oct 18, 2017: Living Cell Technologies: Quarterly Cash Flow Report 30 September 2017 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29
List of Tables
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Living Cell Technologies Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Living Cell Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Living Cell Technologies Enters into Research Agreement with The Centre for Brain Research 11
Living Cell Technologies to Enter into Licensing Agreement with Diatranz Otsuka 12
Living Cell Technologies Enters into Licensing Agreement with Otsuka Pharma 13
Living Cell Technologies to Raise Funds through Share Purchase Plan 14
Living Cell Technologies Raises USD2.8 Million in Private Placement of Shares 15
Otsuka Pharma to Acquire 50% Stake in Diatranz Otsuka from Living Cell Technologies for USD3 Million 16
Living Cell Technologies Ltd, Key Competitors 17
Living Cell Technologies Ltd, Key Employees 18
Living Cell Technologies Ltd, Subsidiaries 19
Living Cell Technologies Ltd, Joint Venture 20
List of Figures
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Living Cell Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9